Changes in TNF inhibitor drug survival in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis over 15 years.

Patients with RA, PsA and AS currently initiating biologic (TNFi) therapy discontinue the drug much sooner than those starting shortly after the drugs were introduced. This is most likely due to the availability of alternative novel b/tsDMARDS treatments and treat-to-target protocols enabling and necessitating earlier switching.